BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kakeji Y, Korenaga D, Tsujitani S, Baba H, Anai H, Maehara Y, Sugimachi K. Gastric cancer with p53 overexpression has high potential for metastasising to lymph nodes. Br J Cancer. 1993;67:589-593. [PMID: 8439509 DOI: 10.1038/bjc.1993.108] [Cited by in Crossref: 94] [Cited by in F6Publishing: 95] [Article Influence: 3.4] [Reference Citation Analysis]
Number Citing Articles
1 Nakamura T, Ide H, Eguchi R, Hayashi K, Hanyu F, Nagasako K, Yukawa M, Asaka K, Fujimori T, Maeda S. Expression of p53 protein related to human papillomavirus and DNA ploidy in superficial esophageal carcinoma. Surg Today 1995;25:591-7. [DOI: 10.1007/bf00311431] [Cited by in Crossref: 14] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
2 Fléjou JF, Muzeau F, Potet F, Lepelletier F, Fékété F, Hénin D. Overexpression of the p53 tumor suppressor gene product in esophageal and gastric carcinomas. Pathol Res Pract. 1994;190:1141-1148. [PMID: 7540752 DOI: 10.1016/s0344-0338(11)80440-1] [Cited by in Crossref: 19] [Cited by in F6Publishing: 11] [Article Influence: 0.7] [Reference Citation Analysis]
3 Baba H, Korenaga D, Kakeji Y, Haraguchi M, Okamura T, Maehara Y. DNA ploidy and its clinical implications in gastric cancer. Surgery 2002;131:S63-70. [DOI: 10.1067/msy.2002.119306] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 1.1] [Reference Citation Analysis]
4 Igarashi N, Takahashi M, Ohkubo H, Omata K, Iida R, Fujimoto S. Predictive value of Ki-67, p53 protein, and DNA content in the diagnosis of gastric carcinoma. Cancer 1999;86:1449-54. [DOI: 10.1002/(sici)1097-0142(19991015)86:8<1449::aid-cncr10>3.0.co;2-d] [Reference Citation Analysis]
5 Peller S, Halevy A, Slutzki S, Kopilova Y, Rotter V. p53 mutations in matched primary and metastatic human tumors. Mol Carcinog 1995;13:166-72. [DOI: 10.1002/mc.2940130306] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 0.8] [Reference Citation Analysis]
6 Kakeji Y, Maehara Y, Tomoda M, Kabashima A, Ohmori M, Oda S, Ohno S, Sugimachi K. Long-term survival of patients with stage IV gastric carcinoma. Cancer 1998;82:2307-11. [PMID: 9635521 DOI: 10.1002/(sici)1097-0142(19980615)82:12<2307::aid-cncr2>3.0.co;2-p] [Cited by in Crossref: 27] [Cited by in F6Publishing: 14] [Article Influence: 1.2] [Reference Citation Analysis]
7 Dalquen P, Sauter G, Torhorst J, Schultheiss E, Jordan P, Lehmann S, Solèr M, Stulz P, Mihatsch MJ, Gudat F. NUCLEAR p53 OVEREXPRESSION IS AN INDEPENDENT PROGNOSTIC PARAMETER IN NODE-NEGATIVE NON-SMALL CELL LUNG CARCINOMA. J Pathol 1996;178:53-8. [DOI: 10.1002/(sici)1096-9896(199601)178:1<53::aid-path415>3.0.co;2-t] [Cited by in Crossref: 32] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
8 Shiota G, Kishimoto Y, Suyama A, Okubo M, Katayama S, Harada K, Ishida M, Hori K, Suou T, Kawasaki H. Prognostic significance of serum anti-p53 antibody in patients with hepatocellular carcinoma. J Hepatol. 1997;27:661-668. [PMID: 9365042 DOI: 10.1016/s0168-8278(97)80083-9] [Cited by in Crossref: 29] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
9 Chang F, Syrjänen S, Tervahauta A, Syrjänen K. Tumourigenesis associated with the p53 tumour suppressor gene. Br J Cancer 1993;68:653-61. [PMID: 8398688 DOI: 10.1038/bjc.1993.404] [Cited by in Crossref: 78] [Cited by in F6Publishing: 76] [Article Influence: 2.8] [Reference Citation Analysis]
10 Seo YH, Joo YE, Choi SK, Rew JS, Park CS, Kim SJ. Prognostic significance of p21 and p53 expression in gastric cancer. Korean J Intern Med. 2003;18:98-103. [PMID: 12872447 DOI: 10.3904/kjim.2003.18.2.98] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 1.1] [Reference Citation Analysis]
11 Lee WJ, Shun CT, Hong RL, Wu MS, Chang KJ, Chen KM. Overexpression of p53 predicts shorter survival in diffuse type gastric cancer. Br J Surg. 1998;85:1138-1142. [PMID: 9718015 DOI: 10.1046/j.1365-2168.1998.00712.x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 0.5] [Reference Citation Analysis]
12 César AC, Borim AA, Caetano A, Cury PM, Silva AE. Aneuploidies, deletion, and overexpression of TP53 gene in intestinal metaplasia of patients without gastric cancer. Cancer Genet Cytogenet 2004;153:127-32. [PMID: 15350302 DOI: 10.1016/j.cancergencyto.2004.01.017] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 0.9] [Reference Citation Analysis]
13 Maehara Y, Kabashima A, Koga T, Tokunaga E, Takeuchi H, Kakeji Y, Sugimachi K. Vascular invasion and potential for tumor angiogenesis and metastasis in gastric carcinoma. Surgery. 2000;128:408-416. [PMID: 10965312 DOI: 10.1067/msy.2000.107265] [Cited by in Crossref: 88] [Cited by in F6Publishing: 84] [Article Influence: 4.2] [Reference Citation Analysis]
14 Maehara Y, Yamamoto M, Oda S, Baba H, Kusumoto T, Ohno S, Ichiyoshi Y, Sugimachi K. Cytokeratin-positive cells in bone marrow for identifying distant micrometastasis of gastric cancer. Br J Cancer 1996;73:83-7. [PMID: 8554989 DOI: 10.1038/bjc.1996.15] [Cited by in Crossref: 39] [Cited by in F6Publishing: 34] [Article Influence: 1.6] [Reference Citation Analysis]
15 Gonçalves AR, Carneiro AJ, Martins I, de Faria PA, Ferreira MA, de Mello EL, Fogaça HS, Elia CC, de Souza HS. Prognostic significance of p53 protein expression in early gastric cancer. Pathol Oncol Res 2011;17:349-55. [PMID: 21116760 DOI: 10.1007/s12253-010-9333-z] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 1.8] [Reference Citation Analysis]
16 Stemmermann G, Heffelfinger SC, Noffsinger A, Hui YZ, Miller MA, Fenoglio-Preiser CM. The molecular biology of esophageal and gastric cancer and their precursors: oncogenes, tumor suppressor genes, and growth factors. Hum Pathol. 1994;25:968-981. [PMID: 7927320 DOI: 10.1016/0046-8177(94)90056-6] [Cited by in Crossref: 82] [Cited by in F6Publishing: 80] [Article Influence: 3.0] [Reference Citation Analysis]
17 Starzynska T, Markiewski M, Domagala W, Marlicz K, Mietkiewski J, Roberts SA, Stern PL. The clinical significance of p53 accumulation in gastric carcinoma. Cancer 1996;77:2005-12. [DOI: 10.1002/(sici)1097-0142(19960515)77:10<2005::aid-cncr7>3.0.co;2-p] [Cited by in Crossref: 26] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
18 Wu CW, Lin YY, Chen GD, Chi CW, Carbone DP, Chen JY. Serum anti-p53 antibodies in gastric adenocarcinoma patients are associated with poor prognosis, lymph node metastasis and poorly differentiated nuclear grade. Br J Cancer 1999;80:483-8. [PMID: 10408857 DOI: 10.1038/sj.bjc.6690382] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 0.8] [Reference Citation Analysis]
19 Friedrich MG, Erbersdobler A, Schwaibold H, Conrad S, Huland E, Huland H. DETECTION OF LOSS OF HETEROZYGOSITY IN THE P53 TUMOR-SUPPRESSOR GENE WITH PCR IN THE URINE OF PATIENTS WITH BLADDER CANCER. Journal of Urology 2000;163:1039-42. [DOI: 10.1016/s0022-5347(05)67878-0] [Cited by in Crossref: 11] [Article Influence: 0.5] [Reference Citation Analysis]
20 Tomoda H, Kakeji Y. Immunohistochemical analysis of p53 in colorectal cancer regarding clinicopathological correlation and prognostic significance. J Surg Oncol 1995;58:125-8. [PMID: 7844983 DOI: 10.1002/jso.2930580211] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 0.6] [Reference Citation Analysis]
21 Maehara Y, Kakeji Y, Watanabe A, Baba H, Kusumoto H, Kohnoe S, Sugimachi K. Clinical implications of serum anti-p53 antibodies for patients with gastric carcinoma. Cancer 1999;85:302-8. [DOI: 10.1002/(sici)1097-0142(19990115)85:2<302::aid-cncr6>3.0.co;2-6] [Cited by in Crossref: 29] [Article Influence: 1.3] [Reference Citation Analysis]
22 Gabbert HE, Müller W, Schneiders A, Meier S, Hommel G. The relationship of p53 expression to the prognosis of 418 patients with gastric carcinoma. Cancer 1995;76:720-6. [DOI: 10.1002/1097-0142(19950901)76:5<720::aid-cncr2820760503>3.0.co;2-e] [Cited by in Crossref: 73] [Cited by in F6Publishing: 27] [Article Influence: 2.8] [Reference Citation Analysis]
23 Kozuki T, Yao T, Nakamura S, Matsumoto T, Tsuneyoshi M. Differences in p53 and cadherin-catenin complex expression between histological subtypes in diffusely infiltrating gastric carcinoma. Histopathology. 2002;41:56-64. [PMID: 12121238 DOI: 10.1046/j.1365-2559.2002.01407.x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 0.9] [Reference Citation Analysis]
24 D'Andrea E, Baffa R, Menin C, Montagna M, Rugge M, Chieco-Bianchi L. TP53 gene mutations in gastric carcinoma detected by polymerase chain reaction/single-strand conformation polymorphism analysis of archival material. J Cancer Res Clin Oncol 1995;121:79-83. [PMID: 7883779 DOI: 10.1007/BF01202217] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
25 Kawabe A, Shimada Y, Uchida S, Maeda M, Yamasaki S, Kato M, Hashimoto Y, Ohshio G, Matsumoto M, Imamura M. Expression of cyclooxygenase-2 in primary and remnant gastric carcinoma: Comparing it with p53 accumulation,Helicobacter pylori infection, and vascular endothelial growth factor expression. J Surg Oncol 2002;80:79-88. [DOI: 10.1002/jso.10107] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 0.9] [Reference Citation Analysis]
26 Mudenda B, Green JA, Green B, Jenkins JR, Robertson L, Tarunina M, Leinster SJ. The relationship between serum p53 autoantibodies and characteristics of human breast cancer. Br J Cancer 1994;69:1115-9. [PMID: 8198980 DOI: 10.1038/bjc.1994.219] [Cited by in Crossref: 60] [Cited by in F6Publishing: 54] [Article Influence: 2.2] [Reference Citation Analysis]
27 Deveci MS, Deveci G. Prognostic value of p53 protein and MK-1 (a tumor-associated antigen) expression in gastric carcinoma. Gastric Cancer. 2007;10:112-116. [PMID: 17577621 DOI: 10.1007/s10120-007-0418-7] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 0.8] [Reference Citation Analysis]
28 Craanen ME, Blok P, Dekker W, Offerhaus GJ, Tytgat GN. Chronology of p53 protein accumulation in gastric carcinogenesis. Gut 1995;36:848-52. [PMID: 7615272 DOI: 10.1136/gut.36.6.848] [Cited by in Crossref: 42] [Cited by in F6Publishing: 45] [Article Influence: 1.6] [Reference Citation Analysis]
29 Ishida M, Gomyo Y, Ohfuji S, Ikeda M, Kawasaki H, Ito H. Evidence that expression of a mutated p53 gene attenuates apoptotic cell death in human gastric intestinal-type carcinomas in vivo. Jpn J Cancer Res. 1997;88:468-475. [PMID: 9247603 DOI: 10.1111/j.1349-7006.1997.tb00405.x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 0.8] [Reference Citation Analysis]
30 Maehara Y, Okuyama T, Kakeji Y, Endo K, Yamamoto M, Sugimachi K. A tumour-associated cell-surface glycoprotein accompanying p53 overexpression and higher growth potential for gastric cancer. Br J Cancer 1995;71:999-1002. [PMID: 7537520 DOI: 10.1038/bjc.1995.192] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 0.5] [Reference Citation Analysis]
31 Hwang HJ, Nam SK, Park H, Park Y, Koh J, Na HY, Kwak Y, Kim WH, Lee HS. Prediction of TP53 mutations by p53 immunohistochemistry and their prognostic significance in gastric cancer. J Pathol Transl Med 2020;54:378-86. [PMID: 32601264 DOI: 10.4132/jptm.2020.06.01] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
32 Maruyama K, Tanaka T, Baba S, Nakamura S, Endo Y, Sugimura H. p53 accumulation in colorectal cancer with hepatic metastasis. Jpn J Cancer Res 1996;87:368-76. [PMID: 8641968 DOI: 10.1111/j.1349-7006.1996.tb00232.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.2] [Reference Citation Analysis]
33 Maehara Y, Oshiro T, Endo K, Baba H, Oda S, Ichiyoshi Y, Kohnoe S, Sugimachi K. Clinical significance of occult micrometastasis lymph nodes from patients with early gastric cancer who died of recurrence. Surgery. 1996;119:397-402. [PMID: 8644003 DOI: 10.1016/s0039-6060(96)80138-3] [Cited by in Crossref: 158] [Cited by in F6Publishing: 75] [Article Influence: 6.3] [Reference Citation Analysis]
34 Fenoglio-Preiser CM, Wang J, Stemmermann GN, Noffsinger A. TP53 and gastric carcinoma: a review. Hum Mutat. 2003;21:258-270. [PMID: 12619111 DOI: 10.1002/humu.10180] [Cited by in Crossref: 160] [Cited by in F6Publishing: 133] [Article Influence: 8.9] [Reference Citation Analysis]
35 Mcculloch PG, Ochiai A, Hirohashi S, O'dowd GM, Nash JRG, Sasako M. Comparison of the molecular genetics ofc-erb-B2 and p53 expression in stomach cancer in Britain and Japan. Cancer 1995;75:920-5. [DOI: 10.1002/1097-0142(19950215)75:4<920::aid-cncr2820750405>3.0.co;2-e] [Cited by in Crossref: 22] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
36 Geyp M, Ireland CM, Pittman SM. Increased tubulin acetylation accompanies reversion to stable ploidy in vincristine-resistant CCRF-CEM cells. Cancer Genetics and Cytogenetics 1996;87:117-22. [DOI: 10.1016/0165-4608(95)00235-9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.4] [Reference Citation Analysis]
37 Kim KW, Kim N, Choi Y, Kim WS, Yoon H, Shin CM, Park YS, Lee DH, Park YS, Ahn SH, Park DJ, Kim HH, Lee HS, Kim JW, Kim JW, Lee KW, Chang W, Park JH, Lee YJ, Lee KH, Kim YH. Different effects of p53 protein overexpression on the survival of gastric cancer patients according to Lauren histologic classification: a retrospective study. Gastric Cancer 2021;24:844-57. [PMID: 33598811 DOI: 10.1007/s10120-021-01163-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
38 Maehara Y, Emi Y, Tomisaki S, Oshiro T, Kakeji Y, Ichiyoshi Y, Sugimachi K. Age-related characteristics of gastric carcinoma in young and elderly patients. Cancer 1996;77:1774-80. [PMID: 8646673 DOI: 10.1002/(SICI)1097-0142(19960501)77:9<1774::AID-CNCR3>3.0.CO;2-C] [Cited by in Crossref: 45] [Cited by in F6Publishing: 23] [Article Influence: 1.8] [Reference Citation Analysis]
39 Craanen ME, Blok P, Offerhaus GJ, Meijer GA, Dekker W, Kuipers EJ, Meuwissen SG. p21(Waf1/Cip1) expression and the p53/MDM2 feedback loop in gastric carcinogenesis. J Pathol 1999;189:481-6. [PMID: 10629547 DOI: 10.1002/(SICI)1096-9896(199912)189:4<481::AID-PATH482>3.0.CO;2-U] [Cited by in Crossref: 13] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
40 Wu MS, Shun CT, Sheu JC, Wang HP, Wang JT, Lee WJ, Chen CJ, Wang TH, Lin JT. Overexpression of mutant p53 and c-erbB-2 proteins and mutations of the p15 and p16 genes in human gastric carcinoma: with respect to histological subtypes and stages. J Gastroenterol Hepatol 1998;13:305-10. [PMID: 9570245 DOI: 10.1111/j.1440-1746.1998.01560.x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 28] [Article Influence: 1.0] [Reference Citation Analysis]
41 Oiwa H, Maehara Y, Ohno S, Sakaguchi Y, Ichiyoshi Y, Sugimachi K. Growth pattern and p53 overexpression in patients with early gastric cancer. Cancer 1995;75:1454-9. [DOI: 10.1002/1097-0142(19950315)75:6+<1454::aid-cncr2820751511>3.0.co;2-g] [Cited by in Crossref: 24] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
42 Triantafillou NG, Grosman IM, Verma RS. Editorial: Genomania of p53 Protein in Gastric Cancer: . Journal of Clinical Gastroenterology 1996;22:170-3. [DOI: 10.1097/00004836-199604000-00003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
43 Seruca R, David L, Castedo S, Veiga I, Børresen A, Sobrinho-simões M. p53 alterations in gastric carcinoma:. Cancer Genetics and Cytogenetics 1994;75:45-50. [DOI: 10.1016/0165-4608(94)90214-3] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 0.4] [Reference Citation Analysis]
44 Kimura O, Sugamura K, Kijima T, Makino M, Shirai H, Tatebe S, Ito H, Kaibara N. Flow cytometric examination of p53 protein in primary tumors and metastases to the liver and lymph nodes of colorectal cancer. Diseases of the Colon & Rectum 1996;39:1428-33. [DOI: 10.1007/bf02054534] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
45 Friedrich &NA; MG, Erbersdobler A, Schwaibold H, Conrad S, Huland E, Huland H. DETECTION OF LOSS OF HETEROZYGOSITY IN THE P53 TUMOR-SUPPRESSOR GENE WITH PCR IN THE URINE OF PATIENTS WITH BLADDER CANCER: . The Journal of Urology. [DOI: 10.1097/00005392-200003000-00093] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.0] [Reference Citation Analysis]
46 Saito H, Osaki T, Murakami D, Sakamoto T, Kanaji S, Ohro S, Tatebe S, Tsujitani S, Ikeguchi M. Prediction of sites of recurrence in gastric carcinoma using immunohistochemical parameters. J Surg Oncol. 2007;95:123-128. [PMID: 17262742 DOI: 10.1002/jso.20612] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 1.4] [Reference Citation Analysis]
47 Würl P, Weigmann F, Meye A, Fittkau M, Rose U, Berger D, Rath FW, Dralle H, Taubert H. Detection of p53 Autoantibodies in Sera of Gastric Cancer Patients and Their Prognostic Relevance. Scandinavian Journal of Gastroenterology 2009;32:1147-51. [DOI: 10.3109/00365529709002995] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 1.8] [Reference Citation Analysis]
48 Seta T, Imazeki F, Yokosuka O, Saisho H, Suzuki T, Koide Y, Isono K. Expression of p53 and p21WAF1/CIP1 proteins in gastric and esophageal cancers: comparison with mutations of the p53 gene. Dig Dis Sci. 1998;43:279-289. [PMID: 9512119 DOI: 10.1023/a:1018889818855] [Cited by in Crossref: 17] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
49 Guan-Zhen Y, Ying C, Can-Rong N, Guo-Dong W, Jian-Xin Q, Jie-Jun W. Reduced protein expression of metastasis-related genes (nm23, KISS1, KAI1 and p53) in lymph node and liver metastases of gastric cancer. Int J Exp Pathol. 2007;88:175-183. [PMID: 17504447 DOI: 10.1111/j.1365-2613.2006.00510.x] [Cited by in Crossref: 49] [Cited by in F6Publishing: 46] [Article Influence: 3.5] [Reference Citation Analysis]
50 Ohashi M, Sugikawa E, Nakanishi N. Inhibition of p53 protein phosphorylation by 9-hydroxyellipticine: a possible anticancer mechanism. Jpn J Cancer Res 1995;86:819-27. [PMID: 7591958 DOI: 10.1111/j.1349-7006.1995.tb03091.x] [Cited by in Crossref: 54] [Cited by in F6Publishing: 38] [Article Influence: 2.1] [Reference Citation Analysis]
51 Kaye P, Radebold K, Isaacs S, Dent D. Expression of p53 and p21waf1/cip1in gastric carcinoma: lack of inter-relationship or correlation with prognosis. European Journal of Surgical Oncology (EJSO) 2000;26:39-43. [DOI: 10.1053/ejso.1999.0738] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 0.8] [Reference Citation Analysis]
52 Allgayer H, Heiss MM, Schildberg FW. Prognostic factors in gastric cancer. Br J Surg. 1997;84:1651-1664. [PMID: 9448610 DOI: 10.1002/bjs.1800841206] [Cited by in Crossref: 60] [Cited by in F6Publishing: 27] [Article Influence: 2.6] [Reference Citation Analysis]
53 Panani AD. Cytogenetic and molecular aspects of gastric cancer: clinical implications. Cancer Lett. 2008;266:99-115. [PMID: 18381231 DOI: 10.1016/j.canlet.2008.02.053] [Cited by in Crossref: 83] [Cited by in F6Publishing: 75] [Article Influence: 6.4] [Reference Citation Analysis]
54 Espinoza LA, Tone LG, Neto JB, Costa RS, Wang QJ, Ballejo G. Enhanced TGFalpha-EGFR expression and P53 gene alterations contributes to gastric tumors aggressiveness. Cancer Lett. 2004;212:33-41. [PMID: 15246559 DOI: 10.1016/j.canlet.2004.03.037] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
55 Graziano F, Cascinu S, Staccioli MP, Catalano V, Rossi MC, Baldelli AM, Giordani P, Muretto P, Catalano G. Potential role and chronology of abnormal expression of the Deleted in Colon Cancer (DCC) and the p53 proteins in the development of gastric cancer. BMC Cancer. 2001;1:9. [PMID: 11518545 DOI: 10.1186/1471-2407-1-9] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 0.8] [Reference Citation Analysis]
56 Yao T, Utsunomiya T, Oya M, Nishiyama K, Tsuneyoshi M. Extremely well-differentiated adenocarcinoma of the stomach: clinicopathological and immunohistochemical features. World J Gastroenterol. 2006;12:2510-2516. [PMID: 16688795 DOI: 10.3748/wjg.v12.i16.2510] [Cited by in CrossRef: 27] [Cited by in F6Publishing: 22] [Article Influence: 1.8] [Reference Citation Analysis]
57 Victorzon M, Nordling S, Haglund C, Lundin J, Roberts P. Expression of p53 protein as a prognostic factor in patients With gastric cancer. European Journal of Cancer 1996;32:215-20. [DOI: 10.1016/0959-8049(95)00547-1] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 1.3] [Reference Citation Analysis]
58 Babacan NA, Egilmez HR, Yücel B, Ilknur P, Seker MM, Kacan T, Bahceci A, Cihan S, Akinci B, Eriten B, Kilickap S. The prognostic value of UHRF-1 and p53 in gastric cancer. Saudi J Gastroenterol 2016;22:25-9. [PMID: 26831603 DOI: 10.4103/1319-3767.173755] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
59 Maehara Y, Kakeji Y, Koga T, Emi Y, Baba H, Akazawa K, Sugimachi K. Therapeutic value of lymph node dissection and the clinical outcome for patients with gastric cancer. Surgery. 2002;131:S85-S91. [PMID: 11821792 DOI: 10.1067/msy.2002.119309] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 0.9] [Reference Citation Analysis]
60 Teng Z, Chen W, Yang D, Zhang Z, Zhu L, Wu F. Expression of p53 in ground-glass nodule of lung cancer and non-lung cancer patients. Oncol Lett 2019;17:1559-64. [PMID: 30675213 DOI: 10.3892/ol.2018.9797] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
61 Fondevila C, Metges JP, Fuster J, Grau JJ, Palacín A, Castells A, Volant A, Pera M. p53 and VEGF expression are independent predictors of tumour recurrence and survival following curative resection of gastric cancer. Br J Cancer. 2004;90:206-215. [PMID: 14710231 DOI: 10.1038/sj.bjc.6601455] [Cited by in Crossref: 125] [Cited by in F6Publishing: 117] [Article Influence: 7.4] [Reference Citation Analysis]
62 Ito H, Ishida M, Ohfuji S, Osaki M, Hayashi H, Tatebe S. Stomach Cancer and Apoptosis: A Review. In: Tahara E, editor. Molecular Pathology of Gastroenterological Cancer. Tokyo: Springer Japan; 1997. pp. 81-92. [DOI: 10.1007/978-4-431-65915-0_8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.0] [Reference Citation Analysis]
63 Mönig SP, Eidt S, Zirbes TK, Stippel D, Baldus SE, Pichlmaier H. p53 expression in gastric cancer: clinicopathological correlation and prognostic significance. Dig Dis Sci 1997;42:2463-7. [PMID: 9440620 DOI: 10.1023/a:1018844008068] [Cited by in Crossref: 21] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
64 Zhang X, Liu L, Yang X, Wang L, Zhang C, Hu Y. Expression of TP53 and IL-1α in unicystic ameloblastoma predicts the efficacy of marsupialization treatment. Medicine (Baltimore) 2018;97:e9795. [PMID: 29419674 DOI: 10.1097/MD.0000000000009795] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
65 Ikawa-Yoshida A, Ando K, Oki E, Saeki H, Kumashiro R, Taketani K, Ida S, Tokunaga E, Kitao H, Morita M, Maehara Y. Contribution of BubR1 to oxidative stress-induced aneuploidy in p53-deficient cells. Cancer Med 2013;2:447-56. [PMID: 24156017 DOI: 10.1002/cam4.101] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
66 Maehara Y, Tomoda M, Hasuda S, Kabashima A, Tokunaga E, Kakeji Y, Sugimachi K. Prognostic value of p53 protein expression for patients with gastric cancer--a multivariate analysis. Br J Cancer 1999;79:1255-61. [PMID: 10098768 DOI: 10.1038/sj.bjc.6690201] [Cited by in Crossref: 43] [Cited by in F6Publishing: 37] [Article Influence: 2.0] [Reference Citation Analysis]
67 Sakar B, Karagol H, Gumus M, Basaran M, Kaytan E, Argon A, Ustuner Z, Bavbek SE, Bugra D, Aykan FN. Timing of Death From Tumor Recurrence After Curative Gastrectomy for Gastric Cancer: . American Journal of Clinical Oncology 2004;27:205-9. [DOI: 10.1097/01.coc.0000092703.12189.a2] [Cited by in Crossref: 35] [Cited by in F6Publishing: 32] [Article Influence: 2.1] [Reference Citation Analysis]
68 Joo YE, Sohn YH, Lee WS, Park CH, Choi SK, Rew JS, Park CS, Kim SJ. Expression of vascular endothelial growth factor and p53 in pancreatic carcinomas. Korean J Intern Med 2002;17:153-9. [PMID: 12298426 DOI: 10.3904/kjim.2002.17.3.153] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
69 Sgambato A, Migaldi M, Leocata P, Ventura L, Criscuolo M, Di Giacomo C, Capelli G, Cittadini A, De Gaetani C. Loss of p27Kip1 expression is a strong independent prognostic factor of reduced survival in N0 gastric carcinomas. Cancer 2000;89:2247-57. [DOI: 10.1002/1097-0142(20001201)89:11<2247::aid-cncr13>3.0.co;2-5] [Cited by in Crossref: 30] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
70 Igarashi N, Takahashi M, Ohkubo H, Omata K, Iida R, Fujimoto S. Predictive value of Ki-67, p53 protein, and DNA content in the diagnosis of gastric carcinoma. Cancer 1999;86:1449-54. [DOI: 10.1002/(sici)1097-0142(19991015)86:8<1449::aid-cncr10>3.0.co;2-d] [Cited by in Crossref: 18] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
71 Ridanpää M, Anttila S, Husgafvel-pursiainen K. Detection of Loss of Heterozygosity in the p53 Tumor Suppressor Gene Using a PCR-based Assay. Pathology - Research and Practice 1995;191:399-402. [DOI: 10.1016/s0344-0338(11)80725-9] [Cited by in Crossref: 5] [Article Influence: 0.2] [Reference Citation Analysis]
72 Cascinu S, Graziano F, Ferro ED, Staccioli MP, Ligi M, Carnevali A, Muretto P, Catalano G. Expression of p53 protein and resistance to preoperative chemotherapy in locally advanced gastric carcinoma. Cancer 1998;83:1917-22. [DOI: 10.1002/(sici)1097-0142(19981101)83:9<1917::aid-cncr6>3.0.co;2-1] [Cited by in Crossref: 49] [Article Influence: 2.1] [Reference Citation Analysis]
73 Endo K, Maehara Y, Ichiyoshi Y, Kusumoto T, Sakaguchi Y, Ohno S, Sugimachi K. Multidrug resistance-associated protein expression in clinical gastric carcinoma. Cancer 1996;77:1681-7. [PMID: 8608562 DOI: 10.1002/(SICI)1097-0142(19960415)77:8<1681::AID-CNCR39>3.0.CO;2-U] [Cited by in Crossref: 16] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
74 Blanchet A, Bourgmayer A, Kurtz JE, Mellitzer G, Gaiddon C. Isoforms of the p53 Family and Gastric Cancer: A Ménage à Trois for an Unfinished Affair. Cancers (Basel) 2021;13:916. [PMID: 33671606 DOI: 10.3390/cancers13040916] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
75 Coffin CM, Hamilton MS, Pysher TJ, Bach P, Ashwood E, Schweiger J, Monahan D, Perry D, Rogers BB, Brugnara C, Rutledge J, Weiss R, Ash O, Hill H, Meikle W, Roberts W, Geaghan S. Pediatric laboratory medicine: current challenges and future opportunities. Am J Clin Pathol 2002;117:683-90. [PMID: 12090415 DOI: 10.1309/NYA1-V9KQ-NVF8-MA8M] [Cited by in Crossref: 16] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
76 Maehara Y, Oshiro T, Adachi Y, Ohno S, Akazawa K, Sugimachi K. Growth pattern and prognosis of gastric cancer invading the subserosa. J Surg Oncol 1994;55:203-8. [PMID: 8159002 DOI: 10.1002/jso.2930550402] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 0.5] [Reference Citation Analysis]
77 Hermanek P, Maruyama K, Sobin LH. Stomach Carcinoma. In: Hermanek P, Gospodarowicz MK, Henson DE, Hutter RVP, Sobin LH, editors. Prognostic Factors in Cancer. Berlin: Springer Berlin Heidelberg; 1995. pp. 47-63. [DOI: 10.1007/978-3-642-79395-0_6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
78 Hayakawa M, Shimokawa K, Kusugami K, Sugihara M, Morooka Y, Fujita T, Nakamura M, Nishio Y, Maeda K, Ando T, Peek RM. Clinicopathological Features of Superficial Depressed-Type Colorectal Neoplastic Lesions. American Journal of Gastroenterology 1999;94:944-9. [DOI: 10.1111/j.1572-0241.1999.991_n.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 0.7] [Reference Citation Analysis]
79 Starzynska T, Marsh P, Stern P. p53 Overexpression as a marker of malignancy in gastric biopsies. Surgical Oncology 1993;2:321-4. [DOI: 10.1016/0960-7404(93)90062-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
80 Müller W, Borchard F. PROGNOSTIC INFLUENCE OF p53 EXPRESSION IN GASTRIC CANCER. J Pathol 1996;178:255-8. [DOI: 10.1002/(sici)1096-9896(199603)178:3<255::aid-path468>3.0.co;2-v] [Cited by in Crossref: 17] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
81 Joo YE, Chung IJ, Park YK, Koh YS, Lee JH, Park CH, Lee WS, Kim HS, Choi SK, Rew JS. Expression of cyclooxygenase-2, p53 and Ki-67 in gastric cancer. J Korean Med Sci. 2006;21:871-876. [PMID: 17043422 DOI: 10.3346/jkms.2006.21.5.871] [Cited by in Crossref: 18] [Cited by in F6Publishing: 23] [Article Influence: 1.3] [Reference Citation Analysis]
82 Hanada K, Itoh M, Fujii K, Tsuchida A, Hirata M, Iwao T, Eguchi N, Sasaki T, Matsubara K, Kajiyama G. TP53 mutations in stage I gallbladder carcinoma with special attention to growth patterns. European Journal of Cancer 1997;33:1136-40. [DOI: 10.1016/s0959-8049(97)00080-4] [Cited by in Crossref: 21] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
83 Meng XM, Zhou Y, Dang T, Tian XY, Kong J. Magnifying chromoendoscopy combined with immunohistochemical staining for early diagnosis of gastric cancer. World J Gastroenterol 2013;19:404-10. [PMID: 23372365 DOI: 10.3748/wjg.v19.i3.404] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
84 Safatle-ribeiro AV, Ribeiro U, Reynolds JC, Gama-rodrigues JJ, Iriya K, Kim R, Bakker A, Swalsky PA, Pinotti HW, Finkelstein SD. Morphologic, histologic, and molecular similarities between adenocarcinomas arising in the gastric stump and the intact stomach. Cancer 1996;78:2288-99. [DOI: 10.1002/(sici)1097-0142(19961201)78:11<2288::aid-cncr4>3.0.co;2-j] [Cited by in Crossref: 15] [Article Influence: 0.6] [Reference Citation Analysis]
85 Ando K, Oki E, Saeki H, Yan Z, Tsuda Y, Hidaka G, Kasagi Y, Otsu H, Kawano H, Kitao H, Morita M, Maehara Y. Discrimination of p53 immunohistochemistry-positive tumors by its staining pattern in gastric cancer. Cancer Med. 2015;4:75-83. [PMID: 25354498 DOI: 10.1002/cam4.346] [Cited by in Crossref: 40] [Cited by in F6Publishing: 35] [Article Influence: 5.7] [Reference Citation Analysis]
86 Shimada K, Ajani JA. Adjuvant therapy for gastric carcinoma patients in the past 15 years: A review of Western and Oriental trials. Cancer 1999;86:1657-68. [DOI: 10.1002/(sici)1097-0142(19991101)86:9<1657::aid-cncr6>3.0.co;2-j] [Cited by in Crossref: 37] [Article Influence: 1.7] [Reference Citation Analysis]
87 Ajani JA, Mansfield PF, Ota DM. Potentially resectable gastric carcinoma: current approaches to staging and preoperative therapy. World J Surg. 1995;19:216-220. [PMID: 7754626 DOI: 10.1007/bf00308629] [Cited by in Crossref: 27] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
88 Pan W, Ishii H, Ebihara Y, Gobe G. Prognostic use of growth characteristics of early gastric cancer and expression patterns of apoptotic, cell proliferation, and cell adhesion proteins. J Surg Oncol 2003;82:104-10. [DOI: 10.1002/jso.10204] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 1.5] [Reference Citation Analysis]
89 Poremba C, W. Yandell D, Mellin W, W. Schmid K, Reers B, Böcker W, Dockhorn-dworniczak B. Adenocarcinoma of the Cardia in a Young Man: Detection of Somatic p53 Mutation by Immunohistochemistry and Automated Direct Sequencing. Pathology - Research and Practice 1995;191:1004-9. [DOI: 10.1016/s0344-0338(11)80599-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
90 Kitayama Y, Sugimura H, Tanaka M, Nakamura S, Kino I. Expression of p53 and flow cytometric DNA analysis of isolated neoplastic glands of the stomach: an application of the gland isolation method. Virchows Arch 1995;426:557-62. [PMID: 7655735 DOI: 10.1007/BF00192109] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
91 Kyokane K, Ito M, Sato Y, Ina K, Ando T, Kusugami K. Expression of Bcl-2 and p53 correlates with the morphology of gastric neoplasia. J Pathol 1998;184:382-9. [PMID: 9664903 DOI: 10.1002/(SICI)1096-9896(199804)184:4<382::AID-PATH1232>3.0.CO;2-F] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
92 Noda H, Maehara Y, Irie K, Kakeji Y, Yonemura T, Sugimachi K. Growth pattern and expressions of cell cycle regulator proteins p53 and p21WAF1/CIP1 in early gastric carcinoma. Cancer 2001;92:1828-35. [DOI: 10.1002/1097-0142(20011001)92:7<1828::aid-cncr1699>3.0.co;2-q] [Cited by in Crossref: 17] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
93 Kim MJ, Kim H. Anticancer Effect of Lycopene in Gastric Carcinogenesis. J Cancer Prev 2015;20:92-6. [PMID: 26151041 DOI: 10.15430/JCP.2015.20.2.92] [Cited by in Crossref: 28] [Cited by in F6Publishing: 11] [Article Influence: 4.7] [Reference Citation Analysis]
94 Sugo H, Takamori S, Kojima K, Beppu T, Futagawa S. The significance of p53 mutations as an indicator of the biological behavior of recurrent hepatocellular carcinomas. Surg Today 1999;29:849-55. [PMID: 10489124 DOI: 10.1007/BF02482774] [Cited by in Crossref: 29] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
95 Allgayer H, Heiss MM, Schildberg FW. Prognostic factors in gastric cancer: PROGNOSTIC FACTORS IN GASTRIC CANCER. Br J Surg 1997;84:1651-64. [DOI: 10.1046/j.1365-2168.1997.00619.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]